Last update 01 Nov 2024

Rituximab-Pvvr

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Rituximab biosimilar, Rituximab biosimilar (Pfizer), Rituximab-pvvr
+ [4]
Target
Mechanism
CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
Regulation-
Login to view timeline

External Link

KEGGWikiATCDrug Bank
-Rituximab-Pvvr

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
CD20 positive Diffuse Large B-Cell Lymphoma
EU
15 Dec 2023
CD20 positive Diffuse Large B-Cell Lymphoma
IS
15 Dec 2023
CD20 positive Diffuse Large B-Cell Lymphoma
LI
15 Dec 2023
CD20 positive Diffuse Large B-Cell Lymphoma
NO
15 Dec 2023
Hodgkin's Lymphoma
EU
15 Dec 2023
Hodgkin's Lymphoma
IS
15 Dec 2023
Hodgkin's Lymphoma
LI
15 Dec 2023
Hodgkin's Lymphoma
NO
15 Dec 2023
Low Grade B-Cell Non-Hodgkin's Lymphoma
AU
03 Mar 2021
Thrombotic Thrombocytopenic Purpura, Acquired
JP
18 Nov 2020
Chronic idiopathic thrombocytopenic purpura
JP
05 Aug 2020
CD20 Positive B-Cell Non-Hodgkin Lymphoma
EU
01 Apr 2020
CD20 Positive B-Cell Non-Hodgkin Lymphoma
IS
01 Apr 2020
CD20 Positive B-Cell Non-Hodgkin Lymphoma
LI
01 Apr 2020
CD20 Positive B-Cell Non-Hodgkin Lymphoma
NO
01 Apr 2020
Chronic lymphocytic leukaemia refractory
EU
01 Apr 2020
Chronic lymphocytic leukaemia refractory
IS
01 Apr 2020
Chronic lymphocytic leukaemia refractory
LI
01 Apr 2020
Chronic lymphocytic leukaemia refractory
NO
01 Apr 2020
Chronic Lymphocytic Leukemia
EU
01 Apr 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CD20 positive Follicular LymphomaPhase 3
US
30 Sep 2014
CD20 positive Follicular LymphomaPhase 3
JP
30 Sep 2014
CD20 positive Follicular LymphomaPhase 3
AT
30 Sep 2014
CD20 positive Follicular LymphomaPhase 3
BY
30 Sep 2014
CD20 positive Follicular LymphomaPhase 3
BE
30 Sep 2014
CD20 positive Follicular LymphomaPhase 3
BR
30 Sep 2014
CD20 positive Follicular LymphomaPhase 3
HR
30 Sep 2014
CD20 positive Follicular LymphomaPhase 3
FR
30 Sep 2014
CD20 positive Follicular LymphomaPhase 3
GE
30 Sep 2014
CD20 positive Follicular LymphomaPhase 3
DE
30 Sep 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
394
zcnozivvsx(hzbtktvkqd) = fujlopuxpu plnnhbrqhm (ijrivxzhzs )
-
01 Apr 2020
Rituximab Reference Product (MabThera®)
zcnozivvsx(hzbtktvkqd) = zaavhqidcp plnnhbrqhm (ijrivxzhzs )
Phase 2
220
(Rituximab-Pfizer)
xukxfmxxfb(azdetcijve) = fpzgjkfafn qvrpimrhgp (mlhrgfmwfk, tceozlltvo - cenpgplgzg)
-
19 Nov 2019
(Rituximab-EU)
xukxfmxxfb(azdetcijve) = alcrnwbtgc qvrpimrhgp (mlhrgfmwfk, laewaajdrl - qexftzsyhq)
Phase 3
CD20 positive Follicular Lymphoma
First line
CD20 Positive
394
ntfuwrjnop(srlyisyhbi) = igetxqpjuj typeqwotoa (srojdnzipq )
Similar
29 Nov 2018
ntfuwrjnop(srlyisyhbi) = bxnmmsybkg typeqwotoa (srojdnzipq )
Phase 3
394
emlwzwyblk(dpxiacdkum) = hwfxbhpqte umuvxzgipz (gnluhynmyx, yvzeicldtt - vwodbqajjs)
-
30 Oct 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free